Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Centessa Pharmaceuticals (Nasdaq: CNTA) on Nov 11, 2025 commenced an underwritten public offering of American Depositary Shares (each ADS representing one ordinary share). All ADSs are being offered by Centessa and the company intends to grant underwriters a 30-day option to purchase up to an additional 15% overallotment. The offering is subject to market and other conditions and there is no assurance it will be completed or as to final size or terms.

Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint book-running managers; Oppenheimer, Truist Securities and LifeSci Capital are co-leads. The ADSs are offered under a Form S-3 registration statement filed Sep 11, 2024 that became automatically effective.

Centessa Pharmaceuticals (Nasdaq: CNTA) said members of management will participate in multiple investor conferences in November–December 2025, giving live fireside chats and webcasts. Key events and times:

• Guggenheim Healthcare Innovation — Nov 12, 2025, 10:30 AM ET
• Jefferies Global Healthcare (London) — Nov 18, 2025, 2:00 PM GMT / 9:00 AM ET
• Piper Sandler Healthcare — Dec 2, 2025, 3:00 PM ET
• Evercore Healthcare — Dec 3, 2025, 9:35 AM ET
• Oppenheimer Movers in Rare Disease Summit — Dec 11, 2025

Access live webcasts and archived recordings via the Events and Publications tab on Centessa's investor relations website.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported Q3 2025 results and clinical updates on its orexin receptor 2 (OX2R) agonist program on November 5, 2025. The company reported $349.0M in cash, cash equivalents and investments as of September 30, 2025, expected to fund operations into mid-2027. Centessa disclosed Phase 2a interim data for ORX750 (55 participants across NT1, NT2, IH) showing statistically significant, dose-dependent improvements on the MWT, ESS and weekly cataplexy rate (example: NT1 1.5 mg cohort, >20 minute MWT change, p=0.0026; 87% WCR reduction, p=0.0025). ORX142 Phase 1 (89 volunteers) showed significant MWT improvements. Company expects to initiate ORX750 registrational program and ORX142/ORX489 patient studies in Q1 2026. Q3 R&D was $41.6M; net loss was $54.9M.

Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management team will engage in a fireside chat on Tuesday, September 9th at 4:50 PM ET.

Investors and interested parties can access the live audio webcast and archived recording through the "Events & Presentations" section on Centessa's investor relations website.

Centessa Pharmaceuticals (NASDAQ:CNTA) reported Q2 2025 financial results and provided updates on its orexin receptor 2 (OX2R) agonist pipeline. The company's lead candidate ORX750 is progressing in Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia, with data expected in 2025. Their second candidate, ORX142, has initiated Phase 1 trials.

Financial highlights include $404.1 million in cash and investments as of June 30, 2025, expected to fund operations into mid-2027. Q2 2025 saw increased R&D expenses of $42.7 million (vs $32.8M in Q2 2024) and a net loss of $50.3 million (vs $43.8M in Q2 2024).

Centessa Pharmaceuticals announced FDA clearance of its IND application for ORX142, a novel orexin receptor 2 agonist. The company will initiate a Phase 1 clinical study in healthy volunteers, with data expected in 2025. ORX142 is being developed for neurological and neurodegenerative disorders and represents the company's second drug candidate in its orexin franchise. The Phase 1 study will assess safety, tolerability, and pharmacokinetics through single and multiple ascending doses, along with a placebo-controlled crossover pharmacodynamic assessment using Maintenance of Wakefulness Test and Karolinska Sleepiness Scale in sleep-deprived subjects. This development complements Centessa's lead OX2R agonist, ORX750, which is advancing in Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia.

Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has announced its management team's participation in two upcoming investor conferences in June 2025:

• The Jefferies 2025 Global Healthcare Conference on June 4, with a fireside chat at 11:40 AM ET
• The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, with a fireside chat at 9:20 AM ET

Live webcasts and archived recordings of both events will be accessible through the \"Events and Publications\" section on Centessa's investor relations website.

Centessa Pharmaceuticals (NASDAQ: CNTA) reported Q1 2025 financial results and business updates, highlighting progress in their orexin receptor 2 (OX2R) agonist pipeline. The company's lead candidate ORX750 is advancing in Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia, with data expected in 2025. Additional Phase 1 data presented at AAN showed sustained effects at 5.0mg dose. ORX142 is preparing for first-in-human studies, while ORX489 advances in IND-enabling studies. Financial highlights include: - Cash position: $424.9M (funding operations into mid-2027) - R&D expenses: $33.4M (vs $22.7M in Q1 2024) - G&A expenses: $12.3M (vs $13.4M in Q1 2024) - Net loss: $26.1M (improved from $38.0M in Q1 2024)

Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q4 and full-year 2024 financial results, highlighting progress in its orexin receptor 2 (OX2R) agonist pipeline. The company's lead candidate, ORX750, showed positive Phase 1 results with significant wakefulness increases in sleep-deprived volunteers and is advancing in Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia.

Financial highlights include:

• Cash position of $482.2M as of December 31, 2024, expected to fund operations into mid-2027
• Q4 2024 R&D expenses increased to $60.9M (vs $29.7M in Q4 2023)
• Full-year 2024 net loss of $235.8M (vs $151.1M in 2023)

The company is advancing two additional compounds: ORX142 in IND-enabling studies with clinical data expected in 2025, and ORX489, their most potent OX2R agonist to date, also in IND-enabling studies.